Article Information
History
- September 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Bernardo García-Carreras1,2,*,
- Matt D. T. Hitchings3,
- Michael A. Johansson4,
- Matthew Biggerstaff4,
- Rachel B. Slayton4,
- Jessica M. Healy4,
- Justin Lessler5,6,
- Talia Quandelacy7,
- Henrik Salje8,
- Angkana T. Huang8 and
- Derek A. T. Cummings1,2
- 1Department of Biology, University of Florida, Gainesville, FL, USA
- 2Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
- 3Department of Biostatistics, University of Florida, Gainesville, FL, USA
- 4COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, GA, USA
- 5Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 6UNC Carolina Population Center, Chapel Hill, NC, USA
- 7University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 8Department of Genetics, University of Cambridge, Cambridge, UK
- ↵*For correspondence:
bgarciacarreras{at}gmail.com (BGC)
Posted September 18, 2022.
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S
